Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Immunome Inc. - Common Stock (IMNM) Institutional Ownership
CUSIP: 45257U108
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
182
Shares (Excl. Options)
118,320,967
Price
$21.48
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- IMNM on Nasdaq
- Shares outstanding
- 109,968,942
- Price per share
- $21.87
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 118,320,967
- Total reported value
- $2,540,583,654
- % of total 13F portfolios
- 0%
- Share change
- +27,000,283
- Value change
- +$630,580,065
- Number of holders
- 182
- Price from insider filings
- $21.87
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- IMNM - Immunome Inc. - Common Stock is tracked under CUSIP 45257U108.
- 182 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 182 to 10 between Q4 2025 and Q1 2026.
- Reported value moved from $2,540,583,654 to $2,652,831.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 182 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 45257U108?
CUSIP 45257U108 identifies IMNM - Immunome Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue With The Right Next Step
- Latest 13F filings - identify new institutional portfolio moves.
- Latest Schedule 13D/13G reports - cross-check beneficial ownership events.
- All institutional ownership pages - compare nearby CUSIPs and holder concentration.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45257U108:
Significant Owners of Immunome Inc. - Common Stock (IMNM) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +113% | $152,894,064 | +$80,670,694 | 13,056,709 | +112% | FMR LLC | 30 Sep 2025 |
| T. Rowe Price Investment Management, Inc. | 12% | $124,649,133 | 10,644,674 | T. Rowe Price Investment Management, Inc. | 31 Oct 2025 | |||
| Redmile Group, LLC | 5.2% | -17% | $122,830,910 | +$7,672,613 | 5,718,385 | +6.7% | Redmile Group, LLC | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 5.9% | $41,638,177 | 4,887,110 | Point72 Asset Management, L.P. | 31 Jan 2025 | |||
| Enavate Sciences GP, LLC | 4.3% | $73,483,864 | 4,768,583 | Enavate Sciences GP, LLC | 18 Dec 2025 | |||
| Immunome Aggregator, LP | 6% | $40,628,327 | 4,768,583 | Immunome Aggregator, LP | 31 Jan 2025 | |||
| EcoR1 Capital, LLC | 4.7% | $34,756,616 | 4,079,415 | EcoR1 Capital, LLC | 31 Mar 2025 | |||
| JANUS HENDERSON GROUP PLC | 2.2% | -55% | $16,313,738 | -$13,130,862 | 1,914,758 | -45% | JANUS HENDERSON GROUP PLC | 31 Mar 2025 |
As of 31 Dec 2025, 182 institutional investors reported holding 118,320,967 shares of Immunome Inc. - Common Stock (IMNM). This represents 108% of the company’s total 109,968,942 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Immunome Inc. - Common Stock (IMNM) together control 92% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 16,549,716 | +27% | 0.02% | $355,487,900 |
| T. Rowe Price Investment Management, Inc. | 12% | 13,421,987 | +59% | 0.18% | $288,305,000 |
| BlackRock, Inc. | 6.9% | 7,594,996 | +30% | 0% | $163,140,515 |
| Point72 Asset Management, L.P. | 6.4% | 7,034,952 | +46% | 0.24% | $151,110,769 |
| VANGUARD GROUP INC | 5.5% | 6,038,414 | +23% | 0% | $129,705,133 |
| Redmile Group, LLC | 5.2% | 5,718,385 | +14% | 9% | $122,830,910 |
| ENAVATE SCIENCES GP, LLC | 4.3% | 4,768,583 | 0% | 20% | $102,429,163 |
| PRIMECAP MANAGEMENT CO/CA/ | 4.3% | 4,685,441 | +55% | 0.08% | $100,643,273 |
| STATE STREET CORP | 3.5% | 3,868,000 | +38% | 0% | $83,084,640 |
| Driehaus Capital Management LLC | 3.4% | 3,705,974 | +432% | 0.54% | $79,604,322 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.1% | 3,380,240 | -9.7% | 0.01% | $72,608,000 |
| JPMORGAN CHASE & CO | 2.6% | 2,855,747 | +8659% | 0% | $61,341,446 |
| EcoR1 Capital, LLC | 2.6% | 2,855,590 | -30% | 2.8% | $61,338,073 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 2,361,381 | +25% | 0% | $50,731,482 |
| Jefferies Financial Group Inc. | 1.8% | 2,000,000 | -4.8% | 0.35% | $42,960,000 |
| READYSTATE ASSET MANAGEMENT LP | 1.7% | 1,843,210 | +40% | 1.8% | $39,592,151 |
| CITADEL ADVISORS LLC | 1.6% | 1,740,705 | +107% | 0.03% | $37,390,343 |
| MORGAN STANLEY | 1.6% | 1,709,089 | -6.8% | 0% | $36,711,252 |
| Sofinnova Investments, Inc. | 1.5% | 1,618,477 | +271% | 1.5% | $34,764,886 |
| Woodline Partners LP | 1.4% | 1,575,398 | +24% | 0.13% | $33,839,549 |
| Balyasny Asset Management L.P. | 1.3% | 1,429,680 | 0.06% | $30,709,526 | |
| PRINCIPAL FINANCIAL GROUP INC | 1.3% | 1,404,450 | +27% | 0.02% | $30,167,586 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1% | 1,126,210 | 3.5% | $24,190,991 | |
| WELLINGTON MANAGEMENT GROUP LLP | 0.85% | 934,463 | +268% | 0% | $20,072,265 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.76% | 840,689 | +27% | 0% | $18,058,000 |
Institutional Holders of Immunome Inc. - Common Stock (IMNM) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 121,247 | $2,652,831 | +$164,326 | $21.87 | 10 |
| 2025 Q4 | 118,320,967 | $2,540,583,654 | +$630,580,065 | $21.48 | 182 |
| 2025 Q3 | 91,384,562 | $1,070,118,014 | +$140,281,752 | $11.71 | 153 |
| 2025 Q2 | 79,431,966 | $738,692,421 | +$30,839,753 | $9.30 | 142 |
| 2025 Q1 | 76,944,016 | $518,447,649 | +$156,654,047 | $6.73 | 141 |
| 2024 Q4 | 53,313,664 | $566,321,086 | -$37,080,544 | $10.62 | 119 |
| 2024 Q3 | 51,629,246 | $754,701,793 | +$58,776,153 | $14.62 | 114 |
| 2024 Q2 | 47,779,242 | $578,110,445 | +$106,966,991 | $12.10 | 112 |
| 2024 Q1 | 36,616,859 | $903,617,775 | +$377,900,927 | $24.68 | 102 |
| 2023 Q4 | 21,490,560 | $229,948,765 | +$205,035,908 | $10.70 | 57 |
| 2023 Q3 | 2,729,076 | $22,706,803 | +$3,521,335 | $8.35 | 36 |
| 2023 Q2 | 1,949,082 | $15,421,801 | +$698,301 | $7.91 | 35 |
| 2023 Q1 | 1,860,095 | $9,343,739 | -$1,198,225 | $4.99 | 30 |
| 2022 Q4 | 2,100,648 | $4,845,087 | -$694,148 | $2.21 | 28 |
| 2022 Q3 | 2,300,040 | $10,208,297 | -$14,594 | $4.43 | 23 |
| 2022 Q2 | 2,313,613 | $7,426,000 | -$1,197,731 | $3.21 | 24 |
| 2022 Q1 | 2,694,238 | $15,433,000 | -$858,955 | $5.68 | 26 |
| 2021 Q4 | 2,790,928 | $36,364,000 | +$4,810,967 | $12.96 | 28 |
| 2021 Q3 | 2,391,433 | $58,321,000 | +$6,054,335 | $24.35 | 31 |
| 2021 Q2 | 2,376,109 | $41,107,000 | +$6,432,363 | $17.30 | 25 |
| 2021 Q1 | 1,909,240 | $64,673,000 | +$1,324,022 | $33.86 | 30 |
| 2020 Q4 | 2,013,500 | $19,489,000 | +$19,489,000 | $9.68 | 24 |